Total Payments
$373,672
2024 Payments
$34,833
Companies
20
Transactions
171
Medicare Patients
624
Medicare Billing
$118,631
Payment Breakdown by Category
Consulting$206,221 (55.2%)
Research$80,348 (21.5%)
Other$52,857 (14.1%)
Travel$30,497 (8.2%)
Food & Beverage$3,729 (1.0%)
Education$19.81 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $206,221 | 38 | 55.2% |
| Unspecified | $80,348 | 8 | 21.5% |
| Travel and Lodging | $30,497 | 36 | 8.2% |
| Honoraria | $28,905 | 7 | 7.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $22,452 | 4 | 6.0% |
| Food and Beverage | $3,729 | 76 | 1.0% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $1,500 | 1 | 0.4% |
| Education | $19.81 | 1 | 0.0% |
Payments by Type
General
$293,324
163 transactions
Research
$80,348
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $120,894 | 27 | $0 (2021) |
| Daiichi Sankyo Inc. | $99,373 | 48 | $0 (2023) |
| Deciphera Pharmaceuticals Inc. | $33,306 | 29 | $0 (2024) |
| EMD Serono, Inc. | $21,915 | 16 | $0 (2020) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $17,812 | 9 | $0 (2023) |
| Servier BioInnovation | $13,480 | 3 | $0 (2023) |
| Boehringer Ingelheim International GmbH | $13,163 | 5 | $0 (2024) |
| EMD Serono Research & Development Institute | $10,708 | 12 | $0 (2017) |
| SERVIER PHARMACEUTICALS LLC | $8,160 | 3 | $0 (2022) |
| Aadi Bioscience, Inc. | $7,965 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $34,833 | 22 | Deciphera Pharmaceuticals Inc. ($13,705) |
| 2023 | $35,681 | 20 | Boehringer Ingelheim Pharmaceuticals, Inc. ($9,452) |
| 2022 | $31,394 | 20 | Boehringer Ingelheim Pharmaceuticals, Inc. ($8,360) |
| 2021 | $41,431 | 12 | Daiichi Sankyo Inc. ($22,813) |
| 2020 | $29,741 | 6 | Daiichi Sankyo Inc. ($25,278) |
| 2019 | $74,744 | 36 | Daiichi Sankyo Inc. ($40,999) |
| 2018 | $83,084 | 25 | Eli Lilly and Company ($68,718) |
| 2017 | $42,763 | 30 | Eli Lilly and Company ($25,897) |
All Payment Transactions
171 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/21/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Honoraria | Cash or cash equivalent | $7,020.00 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $47.50 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $47.50 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $13.88 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $13.88 | General |
| Category: ONCOLOGY | ||||||
| 09/21/2024 | Deciphera Pharmaceuticals Inc. | VIMSELTINIB (Drug) | Honoraria | Cash or cash equivalent | $2,340.00 | General |
| Category: ONCOLOGY | ||||||
| 09/21/2024 | Deciphera Pharmaceuticals Inc. | VIMSELTINIB (Drug) | Travel and Lodging | In-kind items and services | $170.00 | General |
| Category: ONCOLOGY | ||||||
| 09/21/2024 | Deciphera Pharmaceuticals Inc. | VIMSELTINIB (Drug) | Food and Beverage | In-kind items and services | $89.00 | General |
| Category: ONCOLOGY | ||||||
| 09/21/2024 | Deciphera Pharmaceuticals Inc. | VIMSELTINIB (Drug) | Food and Beverage | In-kind items and services | $78.00 | General |
| Category: ONCOLOGY | ||||||
| 08/14/2024 | Boehringer Ingelheim International GmbH | — | Travel and Lodging | In-kind items and services | $414.51 | General |
| 08/14/2024 | Boehringer Ingelheim International GmbH | — | Food and Beverage | In-kind items and services | $49.09 | General |
| 08/14/2024 | Boehringer Ingelheim International GmbH | — | Food and Beverage | In-kind items and services | $32.72 | General |
| 07/17/2024 | Boehringer Ingelheim International GmbH | — | Travel and Lodging | In-kind items and services | $5,266.81 | General |
| 06/01/2024 | Aadi Bioscience, Inc. | — | Honoraria | Cash or cash equivalent | $6,195.00 | General |
| 04/27/2024 | Deciphera Pharmaceuticals Inc. | VIMSELTINIB (Drug) | Honoraria | Cash or cash equivalent | $2,925.00 | General |
| Category: ONCOLOGY | ||||||
| 04/27/2024 | Deciphera Pharmaceuticals Inc. | VIMSELTINIB (Drug) | Travel and Lodging | In-kind items and services | $406.19 | General |
| Category: ONCOLOGY | ||||||
| 04/27/2024 | Deciphera Pharmaceuticals Inc. | VIMSELTINIB (Drug) | Travel and Lodging | In-kind items and services | $235.19 | General |
| Category: ONCOLOGY | ||||||
| 04/27/2024 | Deciphera Pharmaceuticals Inc. | VIMSELTINIB (Drug) | Travel and Lodging | In-kind items and services | $166.43 | General |
| Category: ONCOLOGY | ||||||
| 04/27/2024 | Deciphera Pharmaceuticals Inc. | VIMSELTINIB (Drug) | Food and Beverage | In-kind items and services | $92.16 | General |
| Category: ONCOLOGY | ||||||
| 04/27/2024 | Deciphera Pharmaceuticals Inc. | VIMSELTINIB (Drug) | Food and Beverage | In-kind items and services | $60.48 | General |
| Category: ONCOLOGY | ||||||
| 02/10/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $7,400.00 | General |
| 01/01/2024 | Aadi Bioscience, Inc. | Fyarro (Drug) | Consulting Fee | Cash or cash equivalent | $1,770.00 | General |
| Category: Cancer | ||||||
| 12/20/2023 | Daiichi Sankyo Inc. | Turalio (Drug) | Consulting Fee | Cash or cash equivalent | $3,125.00 | General |
| Category: ONCOLOGY | ||||||
| 12/14/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $9,452.25 | General |
| 12/01/2023 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Consulting Fee | Cash or cash equivalent | $5,265.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AN OPEN-LABEL MULTICENTER PHASE 1A AND 1B STUDY OF OLARATUMAB LY3012207 PLUS PEMBROLIZUMAB MK3475 IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC SOFT TISSUE SARCOMA WHO HAVE FAILED STANDARD TREATMENTS | Eli Lilly and Company | $47,507 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF DOXORUBICIN PLUS OLARATUMAB VERSUS DOXORUBICIN PLUS PLACEBO IN PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUE SARCOMA | Eli Lilly and Company | $19,811 | 1 |
| A PHASE 1B STUDY OF LY3039478 IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | Eli Lilly and Company | $11,366 | 2 |
| STUDY OF ORALLY ADMINISTERED AG-120 IN SUBJECTS WITH ADVANCED SOLID TUMORS, INCLUDING GLIOMA, WITH AN IDH1 MUTATION | SERVIER AFFAIRES MEDICALES | $1,651 | 2 |
| PLX121-01 | Plexxikon Inc. | $13.70 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 124 | 290 | $185,245 | $30,976 |
| 2022 | 4 | 153 | 316 | $209,065 | $35,602 |
| 2021 | 4 | 156 | 269 | $160,595 | $27,621 |
| 2020 | 6 | 191 | 334 | $165,425 | $24,432 |
Total Patients
624
Total Services
1,209
Medicare Billing
$118,631
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 57 | 147 | $107,310 | $18,605 | 17.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 67 | 143 | $77,935 | $12,371 | 15.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 71 | 173 | $128,020 | $22,517 | 17.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 58 | 114 | $62,130 | $10,066 | 16.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 12 | 12 | $12,540 | $2,039 | 16.3% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 12 | 17 | $6,375 | $979.84 | 15.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 64 | 112 | $80,640 | $14,469 | 17.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 63 | 124 | $67,580 | $11,066 | 16.4% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 15 | 17 | $6,375 | $1,079 | 16.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 14 | 16 | $6,000 | $1,007 | 16.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 72 | 160 | $83,200 | $11,411 | 13.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 56 | 72 | $49,680 | $6,792 | 13.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 12 | 35 | $17,325 | $3,321 | 19.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 17 | 29 | $10,295 | $1,392 | 13.5% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 22 | 25 | $3,625 | $1,199 | 33.1% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2020 | 12 | 13 | $1,300 | $317.10 | 24.4% |
About Dr. William Tap, MD
Dr. William Tap, MD is a Hematology & Oncology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1538193446.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. William Tap, MD has received a total of $373,672 in payments from pharmaceutical and medical device companies, with $34,833 received in 2024. These payments were reported across 171 transactions from 20 companies. The most common payment nature is "Consulting Fee" ($206,221).
As a Medicare-enrolled provider, Tap has provided services to 624 Medicare beneficiaries, totaling 1,209 services with total Medicare billing of $118,631. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Internal Medicine, Hematology & Oncology
- Location New York, NY
- Active Since 07/10/2006
- Last Updated 05/25/2011
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1538193446
Products in Payments
- Turalio (Drug) $81,142
- QINLOCK (Drug) $24,363
- Tibsovo (Drug) $9,131
- VIMSELTINIB (Drug) $6,562
- YONDELIS (Drug) $4,635
- TIBSOVO (Drug) $4,080
- Vitrakvi (Drug) $2,100
- Fyarro (Drug) $1,770
- Stivarga (Drug) $1,595
- CYRAMZA (Drug) $231.08
- LARTRUVO (Drug) $136.00
- KEYTRUDA (Biological) $19.81
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in New York
Jeffrey Zwicker, M.d, M.D
Hematology & Oncology — Payments: $1.2M
Hematology & Oncology $1.2M
Manuel Hidalgo Medina, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Ahmed Sawas, M.d, M.D
Hematology & Oncology — Payments: $807,524
Hematology & Oncology $807,524
Ruben Niesvizky, Md, MD
Hematology & Oncology — Payments: $734,512
Hematology & Oncology $734,512
Jeffrey Laurence, Md, MD
Hematology & Oncology — Payments: $706,018
Hematology & Oncology $706,018
Dr. Joshua Sabari, M.d, M.D
Hematology & Oncology — Payments: $603,205
Hematology & Oncology $603,205